Peptides for Women: Complete Guide

Most peptide content is written for men. Dosages assume 80-90kg male bodies. Side effect discussions skip female-specific considerations entirely. If you're a woman researching peptides, this guide is for you.

Weight loss: tirzepatide dosing for women

[[Tirzepatide|10]] works the same way in women as in men (GLP-1/GIP dual agonism). SURMOUNT-1 enrolled both sexes and the results were strong across the board. But two practical differences matter:

Women generally respond to lower doses. Many female participants in trials achieved significant weight loss at 5-10mg/week rather than needing the full 15mg. Starting at 2.5mg and titrating to 5mg is often enough. Lower body weight means the same dose concentration per kg is higher.

Menstrual cycle effects: some women report changes in cycle regularity during the first 1-2 months on GLP-1 peptides. This typically normalizes as the body adjusts. If you're tracking fertility, keep this in mind during the initial phase.

Skin and collagen: GLOW

[[GLOW|23]] (BPC-157 + TB-500 + GHK-Cu) is particularly relevant for women because collagen loss accelerates after menopause. Estrogen directly supports collagen synthesis, and when estrogen drops, skin loses up to 30% of its collagen in the first 5 years post-menopause (Brincat et al., 1987).

GHK-Cu in GLOW stimulates collagen I and III production through gene expression modulation (4000+ genes affected). BPC-157 builds blood supply to skin tissue, and TB-500 drives cell migration for repair. For peri- and post-menopausal women, this combination addresses the collagen gap directly.

Hair thinning: KLOW

Female pattern hair loss affects about 40% of women by age 50. The mechanism often involves scalp inflammation and follicle miniaturization rather than the DHT-driven pattern seen in men.

[[KLOW|20]] targets this through KPV (anti-inflammatory) + BPC-157 (angiogenesis for scalp blood flow) + TB-500 (follicle stem cell activation) + GHK-Cu (tissue repair). The anti-inflammatory component is key for female hair loss because inflammation is usually the primary driver.

Sexual health: PT-141

[[PT-141|19]] (bremelanotide) is the only peptide in this category with specific female clinical data. The RECONNECT Phase III trials studied it in over 1200 premenopausal women with HSDD (hypoactive sexual desire disorder).

Results: significant improvement in satisfying sexual events and desire scores vs placebo. It works through melanocortin receptors in the brain, affecting desire at the central nervous system level. FDA approved in 2019 for this indication.

Dose: 1.75mg subcutaneously, 45-60 minutes before activity. On-demand use, not daily. Main side effect: nausea (~40%, usually mild).

Anti-aging protocol for women

NAD+ ([[NAD+|14]] or [[NAD+ Pen|35]]) for cellular energy and sirtuin activation. Epithalon ([[Epithalon|15]]) for telomere support and melatonin restoration (especially if sleep quality has declined with age). GHK-Cu for collagen and tissue repair.

These three target different aging mechanisms and can be rotated: NAD+ ongoing, epithalon as 10-day courses twice yearly, GHK-Cu in cycles.

Need help?

Building a protocol that accounts for female-specific physiology matters. Dosing, timing around cycles, product selection. Reach out to us and we'll help put something together.

This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.